Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial

被引:89
|
作者
Shi, Mengzhu [1 ]
Miao, Shuai [1 ]
Gu, Tianchu [1 ]
Wang, Dongyue [1 ]
Zhang, Hui [1 ]
Liu, Jindong [2 ]
机构
[1] Xuzhou Med Univ, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Affiliated Hosp, Dept Anesthesiol, 99 Huaihai West Rd, Xuzhou, Jiangsu, Peoples R China
来源
关键词
dexmedetomidine; emergence delirium; postoperative behavioral changes; tonsillectomy; SINGLE-DOSE DEXMEDETOMIDINE; PREOPERATIVE ANXIETY; GENERAL-ANESTHESIA; CHILDREN; AGITATION; TONSILLECTOMY; METAANALYSIS;
D O I
10.2147/DDDT.S196075
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objectives:Emergence delirium (ED) is a common neurologic complication that can not only distress children and their families in the early postanesthetic period, but can also have adverse effects on children in the long-term. This study aimed to investigate the effects of single-dose dexmedetomidine on ED in children with sevoflurane anesthesia and to observe postoperative behavioral changes through long-term follow-up. Methods: Patients aged 2-7 years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy were randomized to receive dexmedetomidine 0.5 mu g/kg(Group D) or volume-matched normal saline (Group C) over 10 minutes after induction of anesthesia. The primary outcome was the incidence of ED within 30 minutes after extubation. Other outcomes were the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs). Results: Ninety children completed the study. Compared with the control group (Group C), dexmedetomidine decreased the incidence of ED (31.1% vs 53.3%; P=0.033) and pain (28.9% vs 57.8%; P=0.006), but it prolonged extubation time (P<0.001). PACU length of stay after extubation and the percentage of adverse events were similar between groups. The incidence of NPOBCs in Group D was significantly lower at 1 and 7 days after discharge (33.3% vs 60.0%; P=0.011% and 24.4% vs 46.7%; P=0.028, respectively) than it was in Group C, but no significant difference was found at the 30th day. Conclusion: Dexmedetomidine 0.5 mu g/kg reduced the incidence of ED after sevoflurane anesthesia and might be used to prevent NPOBCs.
引用
收藏
页码:897 / 905
页数:9
相关论文
共 50 条
  • [41] Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium
    Riegger, Harriet
    Hollinger, Alexa
    Seifert, Burkhardt
    Toft, Katharina
    Blum, Andrea
    Zehnder, Tatjana
    Siegemund, Martin
    TRIALS, 2018, 19
  • [42] Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium
    Harriet Riegger
    Alexa Hollinger
    Burkhardt Seifert
    Katharina Toft
    Andrea Blum
    Tatjana Zehnder
    Martin Siegemund
    Trials, 19
  • [43] Submucosal Injection of Dexmedetomidine Reduces Postoperative Pain in Pediatric Patients Who Underwent Tonsillectomy: A Double-Blind Clinical Trial
    Mozari, Shakiba
    Kalateh, Mahdieh
    Moghadam, Manijeh Yousefi
    Yazdi, Mohammad Shourideh
    Mahmoodi, Rahil
    Foji, Samira
    Shobeiri, Saeideh Sadat
    INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2024, : 385 - 391
  • [44] Seizure length with sevoflurane and thiopental for induction of general anesthesia in electroconvulsive therapy: A randomized double-blind trial
    Rasmussen, Keith G.
    Laurila, Daniel R.
    Brady, Bret M.
    Lewis, Christy L.
    Niemeyer, Kimberly D.
    Sun, Norazlina M.
    Marienau, Marie E. S.
    Hooten, W. Michael
    Schroeder, Darrell R.
    Spackman, Thomas M.
    JOURNAL OF ECT, 2006, 22 (04) : 240 - 242
  • [45] Intraoperative Dexmedetomidine Promotes Postoperative Analgesia and Recovery in Patients after Abdominal Hysterectomy: a Double-Blind, Randomized Clinical Trial
    Dong-Jian Ge
    Bin Qi
    Gang Tang
    Jin-Yu Li
    Scientific Reports, 6
  • [46] Intraoperative Dexmedetomidine Promotes Postoperative Analgesia and Recovery in Patients after Abdominal Hysterectomy: a Double-Blind, Randomized Clinical Trial
    Ge, Dong-Jian
    Qi, Bin
    Tang, Gang
    Li, Jin-Yu
    SCIENTIFIC REPORTS, 2016, 6
  • [47] Intranasal dexmedetomidine improves postoperative sleep quality in older patients with chronic insomnia: a randomized double-blind controlled trial
    Wu, Jinghan
    Liu, Xingyang
    Ye, Chunyan
    Hu, Jiajia
    Ma, Daqing
    Wang, E.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] Effects of intraoperative dexmedetomidine with intravenous anesthesia on postoperative emergence agitation/delirium in pediatric patients undergoing tonsillectomy with or without adenoidectomy A CONSORT-prospective, randomized, controlled clinical trial
    Cao, Jun-Li
    Pei, Yu-Ping
    Wei, Jing-Qiu
    Zhang, Yue-Ying
    MEDICINE, 2016, 95 (49) : e5566
  • [49] Effect of dexmedetomidine on emergence delirium and recovery parameters with sevoflurane and desflurane anaesthesia in children : a double randomized study
    Pandey, Ravinder K.
    Jayaram, A.
    Sharma, Ankur
    Darlong, Vanlal
    Sinha, Renu
    Punj, Jyotsna
    Khokhar, Sudershan K.
    Chowdhury, Apala R.
    Singh, Preet M.
    ACTA ANAESTHESIOLOGICA BELGICA, 2022, 73 (01) : 31 - 38
  • [50] Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
    Jia, Zhen
    Chen, Yi
    Gao, Tianyu
    Yuan, Yuan
    Zheng, Yuxin
    Xie, Yegong
    Wang, Guolin
    Yu, Yonghao
    Zhang, Linlin
    FRONTIERS IN PHARMACOLOGY, 2023, 14